PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw its share price fall more than 20% in the wake of the update.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,